Management

Martin Gerstel has been President and Chief Executive Officer of Compugen since January 1, 2009. From 1997 until his appointment as president & CEO, he served as the company’s Chairman of the Board. In addition, he serves as chairman of two Compugen affiliated companies, Evogene Ltd and Keddem Bioscience, and is a co-founder and co-chairman of Itamar Medical. Prior to relocating to Israel in 1994, Mr. Gerstel was co-chairman and CEO of ALZA Corporation, which he helped found in 1968. He currently serves as a director of Yissum Ltd, Yeda Ltd and the US Foundation for the National Medals of Science and Technology. Mr. Gerstel is a member of the Board of Governors and Executive Committee of the Weizmann Institute of Science and the Board of Governors of the Hebrew University. He is also an advisor to the Burrill Life Sciences Fund and the board of the Israel-U.S. Bi-national Industrial R&D (BIRD)Foundation. Mr. Gerstel holds a B.S. from Yale University and an MBA from Stanford University.

Dr. Cohen-Dayag joined Compugen in 2002, and has held the positions of director of diagnostics, vice president for diagnostic biomarkers & drug targets , and most recently, vice president of R&D. Prior to joining Compugen, she was head of R&D and a member of the executive management at Mindsense Biosystems Ltd. Dr. Cohen-Dayag holds a B.S. in Biology from Ben-Gurion University, and an M.S. in chemical immunology and a Ph.D. in cellular biology from the Weizmann Institute of Science.

Dr. Zangvil joined Compugen in 2006 as Vice President, Business Development. Prior to Compugen, he served as Chief Operating Officer of UltraShape. Previously, Dr. Zangvil was Head of Medical Services of the Israeli Defense Force's Central Command, where he held the rank of Colonel. Prior to this, he held the position of Assistant Director of the Rambam Medical Center in Haifa, Israel. Dr. Zangvil holds an M.D. from the Hebrew University of Jerusalem and specializes in internal medicine. He has a Master's Degree in Health Administration from Tel-Aviv University, Israel.

Zurit Levine joined Compugen in 1999 and has held the positions of director of therapeutic selection and validation, director of therapeutic discovery, and most recently, executive director of R&D. Dr. Levine holds a B.Sc. in Biology from the Tel Aviv University, Israel, and an M.Sc. and Ph.D. in Biochemistry, both from the Tel Aviv University, Israel.

Ms. Dikla Czaczkes Axselbrad joined Compugen in 2008 as chief financial officer. Prior to her current position at Compugen, Ms. Czaczkes Axselbrad served as director of finance for Compugen from 2002 through 2007. Prior to joining Compugen, Ms. Czaczkes Axselbrad was chief financial officer of Packet Technologies Ltd, a mobile internet security hardware and software startup company and before that an audit manager at Ernst & Young Israel. She holds an MBA in finance and a BA in accounting and economics, both from the Tel Aviv University, and is a certified public accountant in Israel.

Dorit Amitay joined the human resources department at Compugen in 1999, bringing with her over ten years of experience. During her tenure at the Company, she took on increasingly larger roles in the HR department until assuming her current position in 2007. Prior to joining Compugen, Ms. Amitay worked for one of Israel’s leading recruitment and placement agencies. She holds a BA and an MBA, both from Ben Gurion University in Israel.